Prevention Of Drug Toxicities With Dichloroacetic Acid - The Implications For Cancer Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$539,839.00
Summary
Many valuable cancer drugs have limited clinical use because of their toxic side effects. Our experiments with a new anti cancer drug called dichloroacetic acid (DCA) will determine if it can reduce the toxic effects of Cisplatin on the kidney and the effects of Doxorubicin on the heart.
Rescuing The Last-line Therapy Colistin Against Gram-negative ‘superbugs’: Increasing The Therapeutic Index By Attenuation Of Nephrotoxicity
Funder
National Health and Medical Research Council
Funding Amount
$498,631.00
Summary
Antibiotic resistance in Gram-negative ‘superbugs’ is presenting a significant global medical challenge. Colistin (polymyxin E) is increasingly used as the last treatment option even though the current use is suboptimal. Simply increasing the daily dose is not an option due to kidney toxicity. This project focuses on a new approach using antioxidants to ameliorate the potential for colistin-induced kidney toxicity, thereby allowing higher doses to achieve adequate bacterial kill in patients.
Lipopeptide Antibiotics For XDR Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$994,897.00
Summary
The polymyxins are a drug class considered to be a last-resort treatment option for multidrug-resistant (MDR) and extremely drug resistant (XDR) Gram-negative infections. Unfortunately resistance is rapidly developing against these antibiotics, leaving no effective therapies and resulting in patient death. This project aims to develop an antibiotic with superior spectra of action and improved safety profiles compared to the polymyxins, with activity against polymyxin-resistant bacteria.
Targeting The Achilles' Heel Of Polymyxins: Eliminating The Nephrotoxicity
Funder
National Health and Medical Research Council
Funding Amount
$673,420.00
Summary
The world is facing a growing threat from the emergence of bacterial 'superbugs' that are resistant to all current antibiotics except the polymyxins. However, kidney toxicity occurs in up to 60% of patients receiving intravenous polymyxins. In this project, we will examine how polymyxins cause kidney toxicity then employ the obtained mechanistic information to decrease this adverse effect. Our study targets the urgent global unmet medical need, lack of new antibiotics for bacterial ‘superbugs’.
Fluid resuscitation is widely used in the management of critically ill patients. There are a variety of different fluids available to doctors but there is little evidence regarding how effective they are. One of the most commonly used fluids, a hydroxyethyl starch was recently approved by the TGA for use in Australia. This project aims to compare how effective and safe this fluid is compared to another widely used fluid, saline, for resuscitation of critically ill patients in intensive care.